Conference No. 4 - Premium - Innovation, bioproduction, and merket authorization: Fabentech at the forefront of the fight against biological threats
Apr 15, 2026 — 05:30 pm - 6:00 PMAuditorium Descartes
Description
As biological threats — whether natural or intentional — continue to rise, the ability to rapidly develop, manufacture and deploy medical countermeasures has become a critical strategic priority for healthcare systems and European sovereignty.
Fabentech is at the forefront of this transformation, developing innovative immunotherapies based on polyclonal antibodies capable of effectively targeting complex and evolving pathogens. This approach, combined with a modular technology platform and integrated biomanufacturing capabilities, significantly accelerates the transition from research to operational deployment.
However, these innovations come with specific challenges, particularly in clinical development, large-scale manufacturing, and market access. In the field of biodefense, traditional regulatory frameworks must evolve to address situations where conventional clinical trials are not feasible, and where strategic stockpiling replaces traditional commercial market dynamics.
Through its experience — including the market authorization of an antidote against ricin — Fabentech demonstrates the need for an integrated approach combining scientific innovation, industrial excellence, and regulatory adaptation.
This panel will explore the key conditions required to build a sustainable and sovereign European model for the development and production of medical countermeasures, strengthening preparedness and response to future health crises.
